Where is the Clinical Breakthrough of Heme Oxygenase-1 / Carbon Monoxide Therapeutics?

  title={Where is the Clinical Breakthrough of Heme Oxygenase-1 / Carbon Monoxide Therapeutics?},
  author={Christopher P. Hopper and Lorenz Meinel and Christoph Steiger and Leo E. Otterbein},
  journal={Current pharmaceutical design},
  volume={24 20},
Heme oxygenase (HO), the rate-limiting step in the degradation of heme to biliverdin, ferrous ion, and carbon monoxide (CO), is an ancestral protective enzyme conserved across phylogenetic domains. While HO was first described in the late 1960s and progressively characterized in the following decades, there has been a surge of innovation over the past twenty years in efforts to leverage the cytoprotective power of HO in a clinical setting. Despite the plethora of preclinical data indicating… 
Adaptive Potential of the Heme Oxygenase/Carbon Monoxide Pathway During Hypoxia
The goal is to describe the importance of examining HO and CO in several systems, the physiological links, and the genetic factors that underlie variation in the HO/CO pathway, suggesting that HO and endogenous CO afford an evolutionary advantage for hypoxia tolerance and are critical in cell survival and injury avoidance.
Therapeutic Potential of Heme Oxygenase-1 and Carbon Monoxide in Acute Organ Injury, Critical Illness, and Inflammatory Disorders
CO, derived from HO activity, has been identified as an endogenous mediator that can influence mitochondrial function and/or cellular signal transduction programs which culminate in the regulation of apoptosis, cellular proliferation, and inflammation.
Carbon monoxide in intensive care medicine—time to start the therapeutic application?!
The current understanding of carbon monoxide’s biology and its possible organ targets to treating the critically ill patients in tomorrow's ICU are summarized.
Role of Heme Oxygenase as a Modulator of Heme-Mediated Pathways
The multitude of pathways regulated by heme will be discussed to enlarge the view on HO and its role in cell physiology and the contribution of HO to pathophysiology, which results from a dysregulated balance between heme and the degradation products formed by HO.
HO-1 and CD39: It Takes Two to Protect the Realm
This review will provide a synopsis of the current state of the field regarding how these enzymes are linked and how they are now being leveraged as therapeutic modalities in the clinic.
Heme oxygenase-1 improves the survival of ischemic skin flaps
Hsp32 improves the survival rate of ischemic skin flaps through anti-inflammatory, anti-oxidant and vasodilatory effects of enzymatic reaction products and discusses the feasibility and existing challenges of HO-1 in flap surgery.
Development of Triggerable, Trackable, and Targetable Carbon Monoxide Releasing Molecules.
ConspectusCarbon monoxide (CO) is a gaseous signaling molecule produced in humans via the breakdown of heme in an O2-dependent reaction catalyzed by heme oxygenase enzymes. A long-lived species